氯氮平合并喹硫平治疗难治性分裂症的对照研究  

A Comparative Study of Clozapine Combined with Quetiapine in the Treatment of Refractory Schizophrenia

作　　者：高玉峰 

机构地区：[1]山东省肥城矿业中心医院,山东肥城271613

出　　处：《中国医学创新》2013年第17期28-30,共3页Medical Innovation of China

摘　　要：目的:评价氯氮平合并喹硫平治疗难治性分裂症的疗效和安全性。方法:将60例难治性分裂症患者随机分为研究组和对照组,分别给予氯氮平合并喹硫平、氯氮平治疗,疗程12周,采用阴性和阳性症状量表(PANSS)及副反应量表(TESS)评定疗效和副反应。结果:对照组显效率为20.0%,总有效率为53.3%;研究组显效率为36.7%,总有效率为80.0%,两组有效率比较差异有统计学意义(P<0.05),而副反应发生率及严重程度研究组明显低于对照组(P<0.05)。结论:氯氮平合并喹硫平治疗难治性分裂症优于单用氯氮平,副作用少且轻。Objective： To study the therapeutic and safety of clozapine combined with quetiapine for patients with refractory schizophrenia. Method： A total of 60 patients with refractory schizophrenia were randomly divided into the groups treated with clozapine combined with quetiapine （ the study group ） or the clozapine （ the contrast group ） respectively.The course of treatment was 12 weeks. The patients were evaluated with PANSS for efficacy and TESS for side effects. Result： The effective rate and improve rate of the study group were 36.7% and 80.0%, and those of the contrast group were 20.0% and 53.3%.There were significant differences between the two groups in the effective rate （P〈0.05 ） .While Side effects incidence and severity of the study group was significantly lower than that of the contrast group.Conclusion： Clozapine combined with quetiapine is an efficacious and safe strategy for treating refractory schizophrenia.

关 键 词：氯氮平 喹硫平 难治性分裂症 

分 类 号：R749.3[医药卫生—神经病学与精神病学]